Diagnostic and prognostic value of biochemical markers in malignant bone disease: A prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease

Clinical Chemistry and Laboratory Medicine

Volumn 36, Issue 11, 1998, Pages 879-885

  Engler, Hanna ^b   Koeberle, Dieter ^b   Thuerlimann, Beat ^b   Senn, Hans Jörg ^b   Riesen, Walter F ^a  

^a Inst of Clin Chem and Hematology   (Switzerland)

^b NONE

Author keywords

Bisphosphonate therapy; Bone markers; Diagnostic markers; Osteolytic bone disease; Prognostic markers

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM ION; DEOXYPYRIDINOLINE; PAMIDRONIC ACID; PYRIDINOLINE;

ADULT; ARTICLE; BLOOD ANALYSIS; BONE ATROPHY; BONE CANCER; BONE METABOLISM; CALCIUM URINE LEVEL; CLINICAL TRIAL; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031773841     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1998.154     Document Type: Article

References (28)

1. Deftos LJ. Bone protein and peptide assays in the diagnosis and management of skeletal disease. Clin Chem 1991; 37:1143-8.
2. Delmas PD. Biochemical markers of bone turnover: methodology and clinical use in osteoporosis. Am J Med 1991; 91 (suppl 5B):59S-63S.
3. Bettica P, Moro L. Biochemical markers of bone metabolism in the assessment of osteoporosis. JIFCC 1995; 7:16-22.
4. Engler H, Thürlimann B, Riesen WF. Biochemical markers of bone remodeling. Onkologie 1996; 19:126-31.
5. Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone disease. Eur J Clin Invest 1991; 21:310-5.
6. Robins SP. Crosslinking of collagen: isolation, structural characterization and glycosylation of pyridinoline. Biochem J 1983; 215:167-73.
7. Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Med 1993; 25:385-93.
8. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39:635-40.
9. Garnero P, Delmas PD. Measurements of biochemical markers: methods and limitations. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic Press, 1997:1277-91.
10. Guise ThA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19:18-54.
11. Besarab A, Caro JF. Mechanism of hypercalcemia in malignancy. Cancer 1978; 41:2276-85.
12. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100.
13. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem 1983; 21:709-20.
14. Seyfried C, Seibel MJ, Woitge HW, Pecherstorfer M, Ziegler R. Biochemische Marker des Knochenstoffwechsels bei Knochenmetastasen. Clin Lab 1996; 42:257-67.
15. Body JJ, Delmas PD. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992; 74:471-5.
16. Coleman RE, Houston S, James I, Rodger A, Rubens RD, Leonard RCF, et al. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer 1992; 65:766-8.
17. Vinholes JJF, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomized trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8:1243-50.
18. Peest D, Deicher H, Fett W, Harms P, Braun HJ, Planker M, et al. Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy - a pilot study of the german myeloma treatment group (GMTG). Eur J Cancer 1996; 32A:2053-7.
19. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995; 10:641-9.
20. Kylmälä T, Tammela TLJ, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995; 71:1061-4.
21. Elomaa I, Risteli L, Laakso M, Lahtinen R, Virkkunen P, Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur J Cancer 1996; 32A:1166-70.
22. Westernhuis LWJJM, Delaere KPJ. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer. Eur J Clin Chem Clin Biochem 1997; 35:89-94.
23. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Application of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80:864-8.
24. Bonde M, Qvist P, Fledelius C, Riis BR, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994; 40:2022-5.
25. Iedelius C, Johnsen AH, Cloos PAC, Bonde M, Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a β-isomerized Asp-Gly sequence within the C-terminal telopeptide (α1) region. J Biol Chem 1997; 272:9755-63.
26. Lowenson J, Clarke S. Does the chemical instability of aspartyl and asparaginyl residues in proteins contribute to erythrocyte aging? Blood Cells 1988; 14:103-17.
27. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, et al. Structural alterations in the peptide backbone of β amyloid core protein may account for its deposition and stability in Alzheimer Disease. J Biol Chem 1993; 268: 3072-83.
28. Garnero P, Fledelius C, Gineyts E, Serre C-M, Vignot E, Delmas PD. Decreased β-isomerization of the C-terminal telopeptide of type I collagen α1 chain in Paget's disease of bone. J Bone Miner Res 1997; 12:1407-15.